目的 評(píng)價(jià)非那雄胺治療經(jīng)尿道前列腺切除術(shù)中出血的效果。方法 按Cochrane 協(xié)作網(wǎng)工作手冊(cè)的要求，制定相應(yīng)的納入/ 排除標(biāo)準(zhǔn)及檢索策略。檢索MEDLINE（1966～2005）、EMbase（1984～2004）、CBM（1980～2005）、Cochrane 圖書館（2005 年第4期）以及相關(guān)雜志和學(xué)位論文，收集非那雄胺治療經(jīng)尿道前列腺切除術(shù)中出血的隨機(jī)和非隨機(jī)對(duì)照試驗(yàn)。對(duì)納入的試驗(yàn)進(jìn)行方法學(xué)質(zhì)量評(píng)價(jià)。采用統(tǒng)一的表格由兩名評(píng)價(jià)員獨(dú)立進(jìn)行資料提取，用RevMan4.2 軟件進(jìn)行數(shù)據(jù)處理和分析。結(jié)果 最終納入5篇文獻(xiàn)：4 個(gè)為隨機(jī)對(duì)照試驗(yàn)，1個(gè)為非隨機(jī)對(duì)照試驗(yàn)。3個(gè)隨機(jī)對(duì)照試驗(yàn)的質(zhì)量等級(jí)均為C級(jí)。Meta分析結(jié)果顯示，兩組年齡、下尿路癥狀評(píng)分、前列腺特異抗體水平及術(shù)前前列腺體積、術(shù)中切除組織量均可比（Pgt;0.05）的情況下，非那雄胺組術(shù)中出血量［WMD –85.44，95%CI（–117.31，–53.58）］、每克切除前列腺組織出血量［WMD –3.5，95%CI（–6.34，–0.58）］，術(shù)前術(shù)后血色素降低量［WMD – 1.61，95%CI（–1.96，–1.26）］均少于對(duì)照組。結(jié)論 現(xiàn)有證據(jù)表明，行經(jīng)尿道前列腺切術(shù)前服用非那雄胺能有效減少術(shù)中出血。
【摘要】 目的 評(píng)價(jià)非那雄胺對(duì)良性前列腺增生（benign prostate hyperplasia，BPH）細(xì)胞外基質(zhì)（extracellular matrixc，ECM）的影響，并探討其作用機(jī)制?！》椒ā?008年6月－2009年3月選擇具備手術(shù)指征的BPH患者20例，按入院順序隨機(jī)分為非那雄胺組和安慰劑組。服藥4周后，行經(jīng)尿道前列腺切除術(shù)（transurethral resection prostate，TURP），留取組織標(biāo)本。另取正常前列腺標(biāo)本6例，用免疫組織化學(xué)法結(jié)合圖像分析系統(tǒng)研究正常組、安慰劑組和非那雄胺組前列腺組織纖維連接蛋白（FN）、膠原（CL）、基質(zhì)金屬蛋白酶2（MMP-2）、金屬蛋白酶組織抑制因子2（TIMP-2）的陽(yáng)性表達(dá)。 結(jié)果 安慰劑組前列腺組織的FN、CL的陽(yáng)性表達(dá)較正常組增強(qiáng)（Plt;0.01），MMP-2/TIMP-2差異無(wú)統(tǒng)計(jì)學(xué)意義（Pgt;0.05）；非那雄胺組與安慰劑組相比，F(xiàn)N、CL的陽(yáng)性表達(dá)減弱（Plt;0.01），而MMP-2/TIMP-2增高（Plt;0.01）?！〗Y(jié)論 非那雄胺能降低BPH組織ECM成分，避免其沉積，其作用機(jī)制可能與其促進(jìn)ECM降解有關(guān)。【Abstract】 Objective To evaluate influence of finasteride on extracellular matrix (ECM) in benign prostate hyperplasia (BPH) patients and study the mechanism. Methods Twenty BPH patients needing surgery were randomly divided into 2 groups according to the sequence of hospitalization from June 2008 to March 2009. The finasteride group and the placebo group had 10 patients each. Transurethral resection prostate (TURP) were performed and the specimens were collected after 4 weeks of drug administration. Moreover, 6 normal prostatic tissues were selected. Expressions of fibronectin (FN), collagen (CL), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) were studied in prostatic tissues in all groups (including the normal group) by immunohistochemistry and image analysis system. Results Expressions of FN and CL were significantly higher than those in the normal group (Plt;0.01), while expressions of MMP-2 and TIMP-2 were not significantly different between them (Pgt;0.05). Compared with the placebo group, expressions of FN and CL in the finateride group were significantly lower than the placebo group (Plt;0.01), while expressions of MMP-2 and TIMP-2 were significantly higher (Plt;0.01). Conclusions BPH is related to ECM depositing. Finasteride can decrease ECM of BPH and refrain it from depositing. Possibly, the principle is that finasteride can promote the degradation of ECM.